MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'World Pharma News' source. Sun, 21 Mar 2010 15:58:24 +0100 http://www.medworm.com/index.php?rid=3384615&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1156%2F29%2F Abbott (NYSE: ABT) announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3384615 Sat, 20 Mar 2010 00:00:00 +0100 3384615 http://www.medworm.com/index.php?rid=3384616&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1155%2F29%2F AstraZeneca announced results of a new analysis of the PLATO study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet BRILINTA (ticagrelor) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3384616 Tue, 16 Mar 2010 00:00:00 +0100 3384616 http://www.medworm.com/index.php?rid=3361282&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1154%2F28%2F 14-16 April 2010, Luxembourg. The Med-e-Tel forum is the ideal opportunity to follow up on the latest developments and initiatives in Telemedicine and eHealth and to exchange ideas and experiences related to ICT applications in healthcare. Register on or before Monday, 15th March, 2010 and get the early bird rate for your Med-e-Tel registration. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3361282 Sat, 13 Mar 2010 00:00:00 +0100 3361282 http://www.medworm.com/index.php?rid=3361283&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1153%2F28%2F 6-7 April 2010, Paris, France. Health 2.0 Europe will take place at the Cité Internationale Universitaire in Paris. This event will feature the three integral components of Health 2.0 in a rapid-fire live demo format where leading examples of Health 2.0 in North America will be compared and contextualized with the latest in European innovation. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3361283 Fri, 12 Mar 2010 00:00:00 +0100 3361283 http://www.medworm.com/index.php?rid=3356893&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1151%2F31%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has completed its acquisition of 100% of Chattem, Inc., which is now a wholly-owned subsidiary of the sanofi-aventis Group. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3356893 Fri, 12 Mar 2010 00:00:00 +0100 3356893 http://www.medworm.com/index.php?rid=3356892&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1152%2F29%2F Pfizer Inc. announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3356892 Fri, 12 Mar 2010 00:00:00 +0100 3356892 http://www.medworm.com/index.php?rid=3356894&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1150%2F27%2F Hospitals in the Middle East are set to benefit from sophisticated electronic clinical decision support following the commercial agreement between First DataBank International (FDB International) and GE Healthcare (GE). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3356894 Thu, 11 Mar 2010 00:00:00 +0100 3356894 http://www.medworm.com/index.php?rid=3352499&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1149%2F29%2F Roche and Biogen Idec announced their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. The decision follows the recommendation of the independent Ocrelizumab RA & Lupus Data and Safety Monitoring Board (DSMB) based on their assessment of the studies in RA (SCRIPT, FEATURE, FILM and STAGE) and lupus (BELONG and BEGIN). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3352499 Thu, 11 Mar 2010 00:00:00 +0100 3352499 http://www.medworm.com/index.php?rid=3348823&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1146%2F29%2F Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3348823 Wed, 10 Mar 2010 00:00:00 +0100 3348823 http://www.medworm.com/index.php?rid=3348822&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1147%2F32%2F Teijin Pharma Limited announced the European launch of TMX-67 (febuxostat), a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3348822 Wed, 10 Mar 2010 00:00:00 +0100 3348822 http://www.medworm.com/index.php?rid=3348821&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1148%2F31%2F Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3348821 Wed, 10 Mar 2010 00:00:00 +0100 3348821 http://www.medworm.com/index.php?rid=3345103&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1144%2F27%2F Trophos, the pharmaceutical company specialising in therapies for orphan diseases including ALS (also known as Lou Gehrig's disease), announces, on behalf of the MitoTarget consortium, the launch of MitoTarget Online. The multilingual web-based resource aims to be the first point of call for all of those affected by ALS. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3345103 Tue, 09 Mar 2010 00:00:00 +0100 3345103 http://www.medworm.com/index.php?rid=3345102&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1145%2F27%2F Google announces an addition to Google Labs - the Public Data Explorer. The purpose of the new tool, Google says on the new lab's page, "The Google Public Data Explorer makes large datasets easy to explore, visualize and communicate. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3345102 Tue, 09 Mar 2010 00:00:00 +0100 3345102 http://www.medworm.com/index.php?rid=3341017&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1142%2F27%2F Physicians will significantly expand the range of activities they conduct on mobile devices by 2012, according to Manhattan Research's "Future of Physician Media" report. Currently physicians primarily use mobile devices to access clinical content and perform quick tasks. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3341017 Mon, 08 Mar 2010 00:00:00 +0100 3341017 http://www.medworm.com/index.php?rid=3341016&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1143%2F27%2F EU-funded researchers have sequenced the genome of the community of microbes that lives in our guts. The study sheds new light on the influence of these microbes on our health and could lead to the development of new treatments and diagnostic tests for a variety of diseases. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3341016 Mon, 08 Mar 2010 00:00:00 +0100 3341016 http://www.medworm.com/index.php?rid=3339318&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1141%2F28%2F 6-7 April 2010, Paris, France. Health 2.0 Europe, a conference dedicated to how Web 2.0 and social media are transforming healthcare systems in Europe, has finalized its agenda and speaker list. Encompassing all aspects of the healthcare chain, the interactive program will address healthcare on both country- and European-wide levels, with local experts from converging industries. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3339318 Sun, 07 Mar 2010 00:00:00 +0100 3339318 http://www.medworm.com/index.php?rid=3333560&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1139%2F30%2F Bristol-Myers Squibb Company (NYSE: BMY) and Allergan, Inc. (NYSE: AGN) announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3333560 Fri, 05 Mar 2010 00:00:00 +0100 3333560 http://www.medworm.com/index.php?rid=3333559&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1140%2F31%2F H. Lundbeck A/S (Lundbeck) announces 2009 results, which meet financial forecasts and continue to show growth in all regions. Full year revenue was DKK 13,747 million and increased 22% at constant exchange rates compared to 2008. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3333559 Fri, 05 Mar 2010 00:00:00 +0100 3333559 http://www.medworm.com/index.php?rid=3329530&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1136%2F32%2F Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Norditropin® FlexPro®, a new prefilled growth hormone injection pen to be used by children and adults. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3329530 Thu, 04 Mar 2010 00:00:00 +0100 3329530 http://www.medworm.com/index.php?rid=3329529&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1137%2F29%2F Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3329529 Thu, 04 Mar 2010 00:00:00 +0100 3329529 http://www.medworm.com/index.php?rid=3329528&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1138%2F29%2F Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) issued a statement following the announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3329528 Thu, 04 Mar 2010 00:00:00 +0100 3329528 http://www.medworm.com/index.php?rid=3325351&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1134%2F29%2F Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3325351 Wed, 03 Mar 2010 00:00:00 +0100 3325351 http://www.medworm.com/index.php?rid=3325350&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1135%2F32%2F Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted 13 to 5 to recommend approval of belatacept, a selective co-stimulation blocker, for the prophylaxis of acute rejection in de novo kidney transplant patients. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3325350 Wed, 03 Mar 2010 00:00:00 +0100 3325350 http://www.medworm.com/index.php?rid=3320458&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1132%2F31%2F Nycomed was on track in 2009, with strong growth in Key Products and most emerging markets. Pantoprazole sales were resilient after the loss of exclusivity in May in 12 European countries, as a result of a tailored approach to each region. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3320458 Tue, 02 Mar 2010 00:00:00 +0100 3320458 http://www.medworm.com/index.php?rid=3320457&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1133%2F27%2F The Research Partnership in Cognitive Aging, a public-private effort to promote the study of brain function with age, will award up to $28 million over five years to 17 research grants to examine the neural and behavioral profiles of healthy cognitive aging and explore interventions that may prevent, reduce or reverse cognitive decline in older people. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3320457 Tue, 02 Mar 2010 00:00:00 +0100 3320457 http://www.medworm.com/index.php?rid=3317441&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1131%2F32%2F GlaxoSmithKline (GSK) responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report") by releasing a White Paper. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3317441 Mon, 01 Mar 2010 00:00:00 +0100 3317441 http://www.medworm.com/index.php?rid=3309652&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1129%2F27%2F Scientists across the world now have access to a powerful new tool not just to present their research, but also to have it discovered by a global audience. No longer do researchers or smaller labs have to worry about their hard work going unnoticed by other scientists, or have to feel restricted to print journals to communicate their ideas. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3309652 Fri, 26 Feb 2010 00:00:00 +0100 3309652 http://www.medworm.com/index.php?rid=3309651&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1130%2F29%2F Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3309651 Fri, 26 Feb 2010 00:00:00 +0100 3309651 http://www.medworm.com/index.php?rid=3304818&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1128%2F32%2F Pfizer Inc (NYSE:PFE) announced that the United States Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) has recommended the use of Prevnar 13™ for healthy children aged 2 months through 59 months for the prevention of invasive pneumococcal disease caused by the 13 pneumococcal serotypes included in the vaccine. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3304818 Thu, 25 Feb 2010 00:00:00 +0100 3304818 http://www.medworm.com/index.php?rid=3300408&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1126%2F27%2F Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. announced the formation of the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3300408 Wed, 24 Feb 2010 00:00:00 +0100 3300408 http://www.medworm.com/index.php?rid=3300407&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1127%2F32%2F Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia(TM) (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3300407 Wed, 24 Feb 2010 00:00:00 +0100 3300407 http://www.medworm.com/index.php?rid=3296783&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1124%2F32%2F Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3296783 Tue, 23 Feb 2010 00:00:00 +0100 3296783 http://www.medworm.com/index.php?rid=3296782&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1125%2F32%2F Novartis announced that Menveo®, a quadrivalent meningococcal conjugate vaccine was approved by the US Food and Drug Administration (FDA) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11 to 55 years of age[1]. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3296782 Tue, 23 Feb 2010 00:00:00 +0100 3296782 http://www.medworm.com/index.php?rid=3293275&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1123%2F32%2F The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone) that are based on analyses that are not consistent with the rigorous scientific evidence supporting the safety of the drug. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3293275 Mon, 22 Feb 2010 00:00:00 +0100 3293275 http://www.medworm.com/index.php?rid=3293276&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1122%2F32%2F GlaxoSmithKline (GSK) rejects the conclusions about the safety of Avandia (rosiglitazone) reported in the February 20, 2010, New York Times story. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3293276 Sun, 21 Feb 2010 00:00:00 +0100 3293276 http://www.medworm.com/index.php?rid=3286107&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1121%2F32%2F GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3286107 Fri, 19 Feb 2010 00:00:00 +0100 3286107 http://www.medworm.com/index.php?rid=3281841&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1119%2F31%2F Genzyme Corp. (NASDAQ: GENZ), a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3281841 Thu, 18 Feb 2010 00:00:00 +0100 3281841 http://www.medworm.com/index.php?rid=3281840&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1120%2F28%2F Health 2.0 Europe will be a unique conference, featuring the three integral components of Health 2.0 in a unique format where leading examples of Health 2.0 in North America will be compared and contextualized with the latest in European innovation. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3281840 Thu, 18 Feb 2010 00:00:00 +0100 3281840 http://www.medworm.com/index.php?rid=3278214&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1118%2F30%2F AstraZeneca and Rigel Pharmaceuticals today announced an exclusive worldwide license agreement for the global development and commercialisation of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3278214 Wed, 17 Feb 2010 00:00:00 +0100 3278214 http://www.medworm.com/index.php?rid=3274586&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1116%2F27%2F EU-funded scientists have discovered that the presence of low levels of a type of antibody in the immune system increases the chance of having a stroke, one of the leading causes of death worldwide. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3274586 Tue, 16 Feb 2010 00:00:00 +0100 3274586 http://www.medworm.com/index.php?rid=3274585&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1117%2F31%2F Abbott (NYSE: ABT) today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key global emerging markets. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3274585 Tue, 16 Feb 2010 00:00:00 +0100 3274585 http://www.medworm.com/index.php?rid=3272029&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1115%2F32%2F Abbott announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3272029 Mon, 15 Feb 2010 00:00:00 +0100 3272029 http://www.medworm.com/index.php?rid=3265163&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1114%2F29%2F Roche has announced that results from the first five Phase III clinical trials show that taspoglutide has met the primary end-points of reduction in blood glucose (blood sugar) in these studies. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3265163 Fri, 12 Feb 2010 00:00:00 +0100 3265163 http://www.medworm.com/index.php?rid=3261163&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1112%2F29%2F Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3261163 Thu, 11 Feb 2010 00:00:00 +0100 3261163 http://www.medworm.com/index.php?rid=3261162&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1113%2F27%2F Lilly USA recently was recognized by the eHealthcare Leadership Awards and the Web Marketing Association for its Health Education Answers program, an interactive health and wellness tool. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3261162 Thu, 11 Feb 2010 00:00:00 +0100 3261162 http://www.medworm.com/index.php?rid=3257089&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1109%2F29%2F Amgen (Nasdaq: AMGN) has announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3257089 Wed, 10 Feb 2010 00:00:00 +0100 3257089 http://www.medworm.com/index.php?rid=3257088&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1110%2F27%2F The Internet has considerably more influence over consumer health decisions and actions than traditional channels like print, TV and radio, according to pharmaceutical and healthcare market research company Manhattan Research's latest report, "Health Influence Mapping: Benchmarking the Influence of Various Sources on Consumer Health Actions." (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3257088 Wed, 10 Feb 2010 00:00:00 +0100 3257088 http://www.medworm.com/index.php?rid=3257087&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1111%2F32%2F AstraZeneca announced that the US Food and Drug Administration (FDA) has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3257087 Wed, 10 Feb 2010 00:00:00 +0100 3257087 http://www.medworm.com/index.php?rid=3252890&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1107%2F28%2F 23-26 March 2010, Munich, Germany. Following its successful premiere in 2008, analytica, the leading trade fair for industrial analysis, laboratory technology and biotechnology, will continue its initiative for new companies again in 2010. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3252890 Tue, 09 Feb 2010 00:00:00 +0100 3252890 http://www.medworm.com/index.php?rid=3252889&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1108%2F27%2F Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3252889 Tue, 09 Feb 2010 00:00:00 +0100 3252889 http://www.medworm.com/index.php?rid=3249643&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1106%2F30%2F GlaxoSmithKline (GSK) has announced the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Over 5,500 rare diseases have been identified(1) of which less than 10% are currently being treated(2), presenting a significant unmet medical need. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3249643 Mon, 08 Feb 2010 00:00:00 +0100 3249643 http://www.medworm.com/index.php?rid=3242021&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1104%2F28%2F Health 2.0 Europe, a conference dedicated to how Web 2.0 and social media are transforming healthcare systems in Europe, will be held, for the first time, on April 6-7, 2010 at the Cité Universitaire International in Paris, France. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3242021 Fri, 05 Feb 2010 00:00:00 +0100 3242021 http://www.medworm.com/index.php?rid=3242020&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1105%2F31%2F The total Roche Group's sales grew by 10% in local currencies (8% in Swiss francs; 7% in US dollars) to 49.1 billion Swiss francs, with the Pharmaceuticals Division accounting for 80% of Group sales and the Diagnostics Division contributing 20%. Sales growth in both divisions exceeded market growth. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3242020 Fri, 05 Feb 2010 00:00:00 +0100 3242020 http://www.medworm.com/index.php?rid=3238012&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1103%2F31%2F Pfizer Inc. (NYSE: PFE) today reported financial results for fourth-quarter and full-year 2009. On October 15, 2009, Pfizer completed the acquisition of Wyeth and, consequently, fourth-quarter and full-year 2009 results include the legacy Wyeth operations from the acquisition date through Pfizer's domestic and international year-ends. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3238012 Thu, 04 Feb 2010 00:00:00 +0100 3238012 http://www.medworm.com/index.php?rid=3238013&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1102%2F27%2F As mobile devices become more advanced, European physicians are turning to them for a number of uses in their professional practice, according to a recent study by Manhattan Research. About half of online European physicians check email on their mobile devices while nearly four in ten search on a mobile web browser. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3238013 Wed, 03 Feb 2010 00:00:00 +0100 3238013 http://www.medworm.com/index.php?rid=3233993&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1101%2F31%2F The U.S. Food and Drug Administration is requesting $4.03 billion to promote and protect public health as part of the President’s fiscal year 2011 budget - a 23 percent increase over the agency’s current $3.28 billion budget. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3233993 Wed, 03 Feb 2010 00:00:00 +0100 3233993 http://www.medworm.com/index.php?rid=3229850&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1100%2F32%2F Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3229850 Tue, 02 Feb 2010 00:00:00 +0100 3229850 http://www.medworm.com/index.php?rid=3226282&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1098%2F31%2F In the fourth quarter of 2009, worldwide total revenue was $5.934 billion, an increase of 14 percent compared with the fourth quarter of 2008. This 14 percent revenue growth was comprised of an increase of 7 percent due to higher volume, 3 percent due to higher prices, and 3 percent due to the impact of foreign exchange rates (numbers do not add due to rounding). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3226282 Mon, 01 Feb 2010 00:00:00 +0100 3226282 http://www.medworm.com/index.php?rid=3226281&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1099%2F30%2F Roche (SIX: RO, ROG; OTCQX: RHHBY) will enter into a strategic alliance with Singapore's scientific and medical institutions to set up a major new translational research hub in Singapore. This "Hub for Translational Medicine" aims to enhance the understanding of how scientific advances from preclinical research can be transferred in practice to patients. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3226281 Mon, 01 Feb 2010 00:00:00 +0100 3226281 http://www.medworm.com/index.php?rid=3218791&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1095%2F31%2F Revenue in the fourth quarter increased by 4 percent at constant exchange rates (CER), but was up 9 percent on an actual basis as a result of the positive impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3218791 Fri, 29 Jan 2010 00:00:00 +0100 3218791 http://www.medworm.com/index.php?rid=3218790&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1096%2F28%2F 29-30 March 2010, Bayer Schering Pharma Headquarters Berlin, Germany. The pharmaceutical/biotech/medical device industry is undergoing significant transformations and the need for meaningful and cost-effective communications is greater than ever. Changes in the political, economic and regulatory environments coupled with revolutions in technology are creating an exciting, yet challenging, atmosphere in which companies must operate. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3218790 Fri, 29 Jan 2010 00:00:00 +0100 3218790 http://www.medworm.com/index.php?rid=3218789&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1097%2F28%2F 29-30 March 2010, Bayer Schering Pharma Headquarters Berlin, Germany. The time has come for a new kind of event that will help the European Pharmaceutical Industry fully explore and engage in the communications revolution that we are witnessing online. Digital Pharma Europe's mission is to help propel the industry into this new era, and Exl Pharma has assembled an outstanding faculty to lead the event. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3218789 Fri, 29 Jan 2010 00:00:00 +0100 3218789 http://www.medworm.com/index.php?rid=3214798&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1093%2F31%2F Worldwide sales increased 10.6 percent to nearly $8.8 billion, including a favorable 2.4 percent effect of exchange rates. Excluding the expected decline in Depakote(R) sales due to generic competition, worldwide reported sales increased 12.7 percent. Full-year 2009 sales were $30.8 billion. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3214798 Thu, 28 Jan 2010 00:00:00 +0100 3214798 http://www.medworm.com/index.php?rid=3214797&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1094%2F30%2F Pfizer Inc. has provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3214797 Thu, 28 Jan 2010 00:00:00 +0100 3214797 http://www.medworm.com/index.php?rid=3210498&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1091%2F31%2F Novartis ended 2009 strongly, delivering double-digit net sales and earnings growth that reflected operational progress in all divisions and more favorable currency conditions over the 2008 period. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3210498 Wed, 27 Jan 2010 00:00:00 +0100 3210498 http://www.medworm.com/index.php?rid=3210497&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1092%2F28%2F 6-7 April 2010, Paris, France. Health 2.0 Europe will be a premier conference, featuring the three integral components of Health 2.0 in a unique format where leading examples of Health 2.0 in North America will be compared and contextualized with the latest in European innovation. The three segments are: (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3210497 Wed, 27 Jan 2010 00:00:00 +0100 3210497 http://www.medworm.com/index.php?rid=3206996&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1090%2F29%2F Bayer Schering Pharma AG, Germany has announced that an independent Data Safety and Monitoring Board (DSMB) has completed an interim analysis of a phase II trial (the LIPLONG study) of the company's long-acting recombinant factor VIII, BAY79-4980. The DSMB concluded that the study will not be able to achieve the predetermined efficacy endpoint (non-inferiority). No safety concerns were raised. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3206996 Tue, 26 Jan 2010 00:00:00 +0100 3206996 http://www.medworm.com/index.php?rid=3203089&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1088%2F32%2F Novo Nordisk announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3203089 Mon, 25 Jan 2010 00:00:00 +0100 3203089 http://www.medworm.com/index.php?rid=3203088&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1089%2F28%2F 10 February 2010, Kurhaus Wiesbaden, Germany. With the 5th Digital Pharma & Life Sciences Conference Microsoft and its partners continue their commitment for the pharmaceutical and chemical industry. The international event focuses on innovative IT solutions and projects for research and development, collaboration as well as life sciences. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3203088 Mon, 25 Jan 2010 00:00:00 +0100 3203088 http://www.medworm.com/index.php?rid=3196042&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1086%2F32%2F Patients in Japan will benefit from the approval of three new Novartis medicines - Equa® (vildagliptin), marketed as Galvus® in the European Union, for the treatment of type 2 diabetes, Exforge® (valsartan/amlodipine) for high blood pressure, and Afinitor® (everolimus) for advanced kidney cancer. These approvals reinforce the strong commitment of Novartis to helping patients in Japan, the company's second-largest pharmaceutical market. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3196042 Fri, 22 Jan 2010 00:00:00 +0100 3196042 http://www.medworm.com/index.php?rid=3196041&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1087%2F30%2F In the face of the unprecedented earthquake that hit the island of Haiti, sanofi-aventis has committed 1 million Euros in financial aid to long-term reconstruction initiatives and the rehabilitation of the population of Haiti. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3196041 Fri, 22 Jan 2010 00:00:00 +0100 3196041 http://www.medworm.com/index.php?rid=3191645&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1085%2F30%2F Bristol-Myers Squibb is joining the world community in providing immediate help for survivors of the massive earthquake that struck Haiti on January 12. The company has already shipped a large donation of antibiotics through Project Hope, an organization providing direct relief to disaster victims. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3191645 Thu, 21 Jan 2010 00:00:00 +0100 3191645 http://www.medworm.com/index.php?rid=3187601&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1083%2F30%2F Working directly with humanitarian partners to help address the growing health care crisis, Abbott (NYSE: ABT) is expanding its support for relief efforts in Haiti. The company will provide $2.5 million in grant funding and donations of critical pharmaceutical and nutritional products to humanitarian aid organizations. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3187601 Wed, 20 Jan 2010 00:00:00 +0100 3187601 http://www.medworm.com/index.php?rid=3187600&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1084%2F30%2F Eli Lilly and Company (NYSE: LLY) will provide donations of medicines and money for victims of the catastrophic earthquake in Haiti on January 12. Lilly has initially pledged $250,000 in direct cash contributions. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3187600 Wed, 20 Jan 2010 00:00:00 +0100 3187600 http://www.medworm.com/index.php?rid=3184207&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1082%2F30%2F Through its local organizations in countries throughout the region, Novartis is providing the equivalent of over USD 2.5 million in immediate emergency aid for victims of the recent earthquake in Haiti. The support includes both direct financial aid to relief agencies working in Haiti as well as donations of essential medicines, including antibiotic and pain relieving drugs. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3184207 Tue, 19 Jan 2010 00:00:00 +0100 3184207 http://www.medworm.com/index.php?rid=3181167&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1081%2F28%2F 6-7 April 2010, Paris, France. Health 2.0 Europe, known for its live demos, will assemble speakers from 12 European countries and the U.S., in order to explain the world of Web 2.0 (both computer and mobile) in health care with its patient and professional communities, online consultation, rating sites, personal health records, specialized search engines, prevention programs. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3181167 Mon, 18 Jan 2010 00:00:00 +0100 3181167 http://www.medworm.com/index.php?rid=3179824&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1080%2F28%2F 11-14 July 2010, Dresden, Germany. 3rd International Congress on Stem Cells and Tissue Formation will focus on stem cells including their niches, reprogramming and the formation of tissues of multiple organs, such as the CNS, pancreas, skin, heart and the hematopoietic system. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3179824 Sun, 17 Jan 2010 00:00:00 +0100 3179824 http://www.medworm.com/index.php?rid=3174162&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1079%2F30%2F Amgen (Nasdaq: AMGN) announced that the company will donate $2 million to Haiti relief efforts. Amgen staff are being encouraged to be generous and that effort should also generate meaningful additional support. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3174162 Fri, 15 Jan 2010 00:00:00 +0100 3174162 http://www.medworm.com/index.php?rid=3174163&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1078%2F30%2F Abbott (NYSE: ABT) and its philanthropic foundation the Abbott Fund have committed to provide $1 million in initial humanitarian aid in response to the earthquake in Haiti. This support includes grant funding and donations of critical pharmaceutical and nutritional products to strengthen the ability of humanitarian aid organizations to respond to immediate health needs in Haiti. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3174163 Thu, 14 Jan 2010 00:00:00 +0100 3174163 http://www.medworm.com/index.php?rid=3169676&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1076%2F27%2F NuvaRing® and Latisse® are the top pharmaceutical brands in terms of having the highest percentage of overall product website traffic driven by their DTC television advertisements, according to pharmaceutical and healthcare market research company Manhattan Research. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3169676 Thu, 14 Jan 2010 00:00:00 +0100 3169676 http://www.medworm.com/index.php?rid=3169675&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1077%2F29%2F Novo Nordisk has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose proprietary Eligen® Technology is used in the formulation of NN9924. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3169675 Thu, 14 Jan 2010 00:00:00 +0100 3169675 http://www.medworm.com/index.php?rid=3165745&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1074%2F31%2F Genzyme Corp. (NASDAQ: GENZ) reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008. For the year, revenue was $4.5 billion compared with $4.6 billion in 2008. Excluding the Genetic Disease business, which was affected by a product supply interruption, fourth-quarter revenue grew 24 percent compared with the same period in 2008 and full-year revenue grew 15 percent. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3165745 Wed, 13 Jan 2010 00:00:00 +0100 3165745 http://www.medworm.com/index.php?rid=3165744&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1075%2F32%2F Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States (US) Food and Drug Administration (FDA) approved ACTEMRA (tocilizumab, RoACTEMRA in the European Union) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3165744 Wed, 13 Jan 2010 00:00:00 +0100 3165744 http://www.medworm.com/index.php?rid=3162168&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1073%2F32%2F Novartis announced that Fanapt(TM) (iloperidone) tablets are now available for use across the US for the acute treatment of schizophrenia in adults. Fanapt is a twice-daily, oral antipsychotic, approved by the US Food and Drug Administration (FDA) in May 2009. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3162168 Tue, 12 Jan 2010 00:00:00 +0100 3162168 http://www.medworm.com/index.php?rid=3158864&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1071%2F28%2F 14-16 April 2010, Luxembourg. Join Med-e-Tel 2010 and actively participate in the educational and information program of seminars, demonstrations and interactive panel discussions on eHealth, telemedicine and ICT applications in medicine and healthcare. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3158864 Mon, 11 Jan 2010 00:00:00 +0100 3158864 http://www.medworm.com/index.php?rid=3158863&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1072%2F32%2F Abbott (NYSE: ABT) announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. Japan is the second largest drug eluting stent market in the world after the United States, with approximately 200,000 stent procedures performed each year. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3158863 Mon, 11 Jan 2010 00:00:00 +0100 3158863 http://www.medworm.com/index.php?rid=3151272&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1070%2F32%2F AstraZeneca has entered into an agreement with Teva Pharmaceutical Industries Ltd. and affiliates (collectively "Teva") to settle patent litigation regarding Teva's proposed generic version of AstraZeneca's Nexium delayed-release capsules (esomeprazole magnesium). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3151272 Fri, 08 Jan 2010 00:00:00 +0100 3151272 http://www.medworm.com/index.php?rid=3147717&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1069%2F30%2F Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ownership interest. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3147717 Thu, 07 Jan 2010 00:00:00 +0100 3147717 http://www.medworm.com/index.php?rid=3144471&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1068%2F30%2F Luitpold Pharmaceuticals, Inc., a New York based U.S. Company of Daiichi Sankyo Co., Ltd. (Corporate Headquarters: Tokyo, Japan) and PharmaForce, Inc., (Columbus, Ohio, USA), a privately-held fullyintegrated specialty injectable pharmaceutical company, announced today that PharmaForce has been acquired by Luitpold. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3144471 Wed, 06 Jan 2010 00:00:00 +0100 3144471 http://www.medworm.com/index.php?rid=3141000&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1067%2F27%2F A large-scale study has identified five new genetic loci (points on the genome) associated with the health of the human lung and pulmonary function. Publishing in the latest edition of the journal Nature Genetics, the partly EU-funded researchers explain that their findings shed new light on the molecular basis of lung disease and might lead to better treatment of chronic obstructive pulmonary disease (COPD), asthma and similar conditions. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3141000 Tue, 05 Jan 2010 00:00:00 +0100 3141000 http://www.medworm.com/index.php?rid=3138388&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1066%2F32%2F Novartis announced that the World Health Organization (WHO) has granted prequalification for all three of its influenza A(H1N1) 2009 monovalent vaccines for supply to United Nations (UN) agencies: the cell culture-based and MF59® adjuvanted vaccine Celtura®, the egg-based and MF59 adjuvanted vaccine Focetria® as well as the egg-based A(H1N1) vaccine manufactured using the seasonal Fluvirin® platform. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3138388 Mon, 04 Jan 2010 00:00:00 +0100 3138388 http://www.medworm.com/index.php?rid=3137144&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1065%2F32%2F Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company's candidate 13-valent pneumococcal conjugate vaccine. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3137144 Sun, 03 Jan 2010 00:00:00 +0100 3137144 http://www.medworm.com/index.php?rid=3109858&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1064%2F31%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Chattem, Inc. (NASDAQ: CHTT) have entered into a definitive agreement under which sanofi-aventis is to acquire 100 percent of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3109858 Tue, 22 Dec 2009 00:00:00 +0100 3109858 http://www.medworm.com/index.php?rid=3107665&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1063%2F32%2F Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3107665 Mon, 21 Dec 2009 00:00:00 +0100 3107665 http://www.medworm.com/index.php?rid=3098751&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1062%2F30%2F Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Stapyhylococcus aureus or MRSA. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3098751 Fri, 18 Dec 2009 00:00:00 +0100 3098751 http://www.medworm.com/index.php?rid=3094727&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1061%2F30%2F GlaxoSmithKline published a list of fees paid between April 1 and June 30 to U.S. healthcare professionals for speaking and consulting services. GSK will update this list quarterly going forward. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3094727 Thu, 17 Dec 2009 00:00:00 +0100 3094727 http://www.medworm.com/index.php?rid=3091304&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1059%2F30%2F Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Inc. ("Pfizer") announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos® (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3091304 Wed, 16 Dec 2009 00:00:00 +0100 3091304 http://www.medworm.com/index.php?rid=3091303&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1060%2F30%2F Array BioPharma Inc. (Nasdaq: ARRY) and Amgen Inc.(Nasdaq: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3091303 Wed, 16 Dec 2009 00:00:00 +0100 3091303 http://www.medworm.com/index.php?rid=3087723&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1057%2F27%2F A new solution developed by IBM (NYSE: IBM), Novartis and Vodafone with the Roll Back Malaria Partnership, is helping to save lives using everyday technology to improve the availability of anti-malarial drugs in remote areas of Tanzania. Called "SMS for Life", the initiative uses a combination of mobile phones, SMS (Short Messaging Service) technologies and intuitive web sites to track and manage the supply of Artemisinin-based Combination Therapy (ACT) drugs and Quinine injectables, both of which are key to reducing the number of deaths from malaria. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3087723 Tue, 15 Dec 2009 00:00:00 +0100 3087723 http://www.medworm.com/index.php?rid=3087722&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1058%2F30%2F Abbott (NYSE: ABT) announced today a definitive agreement to acquire STARLIMS Technologies Ltd. (Nasdaq: LIMS), a leading provider of laboratory information management systems, for approximately $123 million in cash. The acquisition strengthens Abbott's competitive position in the global diagnostics market, providing advanced web-based applications to help laboratories efficiently store, retrieve and analyze a significantly increasing volume of clinical, managerial and administrative data. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3087722 Tue, 15 Dec 2009 00:00:00 +0100 3087722 http://www.medworm.com/index.php?rid=3083761&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1056%2F30%2F GlaxoSmithKline Biologicals SA (GSK) and Intercell announced an agreement to form a strategic alliance to accelerate the development and commercialisation of needle-free, patch-based vaccines. The agreement will include Intercell's candidate vaccine for travellers' diarrhoea (TD) and an investigational single application pandemic influenza vaccine, as well as the use of the patch technology for other vaccines in GSK's portfolio. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3083761 Mon, 14 Dec 2009 00:00:00 +0100 3083761 http://www.medworm.com/index.php?rid=3077738&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1054%2F27%2F While most marketers have accepted that nearly all physicians are online today, the more difficult part is figuring out where to find these physicians on the World Wide Web. Finding the right promotional mix for connecting with physicians can be a challenging proposition, as physicians use third-party sites - such as the WebMD Professional Network, the New England Journal of Medicine, or specialty specific sites - more frequently than they use pharma-owned properties. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3077738 Fri, 11 Dec 2009 00:00:00 +0100 3077738 http://www.medworm.com/index.php?rid=3077737&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1055%2F30%2F Pfizer will extend its MAINTAIN™ (Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010. In addition to the more than 70 Pfizer primary care medicines currently available through MAINTAIN, Pfizer will extend the benefits of MAINTAIN to many legacy Wyeth medicines. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3077737 Fri, 11 Dec 2009 00:00:00 +0100 3077737 http://www.medworm.com/index.php?rid=3073779&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1053%2F27%2F Pfizer announced today results of a survey the company recently sponsored that shows physicians are more likely to report side effects through an electronic health records (EHR) system, as compared to traditional paper methods. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3073779 Thu, 10 Dec 2009 00:00:00 +0100 3073779 http://www.medworm.com/index.php?rid=3069407&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1052%2F29%2F In a large Phase III clinical trial, Tasigna® (nilotinib) demonstrated greater efficacy over Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase[1]. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3069407 Wed, 09 Dec 2009 00:00:00 +0100 3069407 http://www.medworm.com/index.php?rid=3065484&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1050%2F29%2F Novo Nordisk has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a USD 2 million payment to Merrion Pharmaceuticals plc, whose GIPET® technology is used in the formulation of NN1952. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3065484 Tue, 08 Dec 2009 00:00:00 +0100 3065484 http://www.medworm.com/index.php?rid=3065483&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1051%2F29%2F Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3065483 Tue, 08 Dec 2009 00:00:00 +0100 3065483 http://www.medworm.com/index.php?rid=3062390&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1049%2F30%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer's disease. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3062390 Mon, 07 Dec 2009 00:00:00 +0100 3062390 http://www.medworm.com/index.php?rid=3060701&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1048%2F27%2F Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Community. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3060701 Sun, 06 Dec 2009 00:00:00 +0100 3060701 http://www.medworm.com/index.php?rid=3054838&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1047%2F30%2F AstraZeneca and Targacept, Inc. announced a collaboration and licence agreement for the global development and commercialisation of TC-5214, Targacept's late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently completed a phase IIb clinical trial, is a nicotinic channel blocker that is thought to treat depression by modulating the activity of various neuronal nicotinic receptor (NNR) subtypes. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3054838 Fri, 04 Dec 2009 00:00:00 +0100 3054838 http://www.medworm.com/index.php?rid=3050546&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1045%2F32%2F GlaxoSmithKline (GSK) announced that the World Health Organization (WHO) has awarded prequalification for global use of Arepanrix™, GSK's adjuvanted H1N1 pandemic vaccine manufactured in Canada. This is the first prequalification for an H1N1 pandemic vaccine, and is a key step in ensuring the vaccine can be distributed to developing countries. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3050546 Thu, 03 Dec 2009 00:00:00 +0100 3050546 http://www.medworm.com/index.php?rid=3050545&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1046%2F27%2F The educational resource, "The Value of Medicine, Improving Health... Improving Life," created by Lilly USA (NYSE: LLY), is now available for download. The booklet supports Lilly's commitment to providing "Answers That Matter" and encourages an open dialogue with patients, providers, payers and the public about pharmaceutical industry practices. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3050545 Thu, 03 Dec 2009 00:00:00 +0100 3050545 http://www.medworm.com/index.php?rid=3046733&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1043%2F30%2F Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher's disease. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3046733 Wed, 02 Dec 2009 00:00:00 +0100 3046733 http://www.medworm.com/index.php?rid=3046732&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1044%2F32%2F Merck KGaA announced that its US affiliate received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3046732 Wed, 02 Dec 2009 00:00:00 +0100 3046732 http://www.medworm.com/index.php?rid=3042530&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1040%2F29%2F Bayer Schering Pharma AG, Germany, is progressing with the development of florbetaben to support Alzheimer diagnosis. On the occasion of the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the company announced the enrollment of first patients in an international clinical Phase III trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid deposition in the brain. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3042530 Tue, 01 Dec 2009 00:00:00 +0100 3042530 http://www.medworm.com/index.php?rid=3042529&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1041%2F27%2F The National AIDS Fund (NAF) and Bristol-Myers Squibb Company (NYSE: BMY) announced their intention to launch "Positive Charge", a new multiyear initiative aimed at helping to break down the barriers that prevent people living with HIV from receiving HIV care, treatment and necessary support. The initiative is slated to launch in January 2010. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3042529 Tue, 01 Dec 2009 00:00:00 +0100 3042529 http://www.medworm.com/index.php?rid=3042528&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1042%2F27%2F On this World AIDS Day we are filled with both hope and concern. Hope because significant progress has been made towards universal access. New HIV infections have dropped. Fewer children are born with HIV. And more than 4 million people are on treatment. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3042528 Tue, 01 Dec 2009 00:00:00 +0100 3042528 http://www.medworm.com/index.php?rid=3038252&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1038%2F29%2F H. Lundbeck A/S announced the initiation of a multi-centre, placebo-controlled, fixed-dose study of Lu AE58054 as add-on to donepezil in patients with moderate Alzheimer's disease. The clinical phase II study is planned to enrol approximately 270 patients. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3038252 Mon, 30 Nov 2009 00:00:00 +0100 3038252 http://www.medworm.com/index.php?rid=3038251&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1039%2F30%2F Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effective treatment options. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3038251 Mon, 30 Nov 2009 00:00:00 +0100 3038251 http://www.medworm.com/index.php?rid=3032506&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1037%2F28%2F Webinar: December 1 & December 10, 2009. Every day academics, diagnostic developers, biotech and pharma companies get closer to scientific breakthroughs in technology and methods that are applicable to oncology treatments. Given the sheer volume of such discoveries, it is becoming increasingly difficult for potential stakeholders to become aware of these advances and remain updated. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3032506 Fri, 27 Nov 2009 00:00:00 +0100 3032506 http://www.medworm.com/index.php?rid=3028475&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1035%2F27%2F The brain disease X-linked adrenoleukodystrophy (ALD) can be treated with a combination of gene therapy and blood stem cell therapy, new EU-funded research shows. The research is part of the X-ALD (X-linked adrenoleukodystrophy: pathogenesis, animal models and therapy) project, which received EUR 1.8 million under the 'Life sciences, genomics and biotechnology for health' Thematic area of the EU's Sixth Framework Programme (FP6). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3028475 Thu, 26 Nov 2009 00:00:00 +0100 3028475 http://www.medworm.com/index.php?rid=3028474&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1036%2F28%2F Bayer Schering Pharma and ExL Pharma announced that the 2nd Annual Digital Pharma Europe and 2nd Annual European Public Relations and Communications Summit will be hosted at the Bayer Schering Pharma World Headquarters in Berlin, Germany on March 29-30, 2010. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3028474 Thu, 26 Nov 2009 00:00:00 +0100 3028474 http://www.medworm.com/index.php?rid=3025059&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1034%2F32%2F TikoMed AB, a biotechnology company focused on development and commercialization of innovative treatments for immune diseases and cell therapies, today announced that IBsolvMIR® has been granted orphan drug designation for the prevention of graft rejection of pancreatic islet transplantation by the U.S. Food and Drug Administration (FDA). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3025059 Wed, 25 Nov 2009 00:00:00 +0100 3025059 http://www.medworm.com/index.php?rid=3025060&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1033%2F30%2F Today, Novartis officially inaugurated the US's first ever large-scale flu cell culture vaccine and adjuvant manufacturing facility in Holly Springs, North Carolina. The facility is a result of a partnership between Novartis and the US Department of Health and Human Services (HHS). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3025060 Tue, 24 Nov 2009 00:00:00 +0100 3025060 http://www.medworm.com/index.php?rid=3021385&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1032%2F30%2F Merck KGaA announced plans to strengthen its global research and development (R&D) capabilities of its Merck Serono division by establishing a global R&D center in Beijing, China. Merck is planning to invest more than € 150 million and create more than 200 new qualified jobs over the next four years to set up the China R&D center and conduct R&D activities in China. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3021385 Tue, 24 Nov 2009 00:00:00 +0100 3021385 http://www.medworm.com/index.php?rid=3018050&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1031%2F32%2F Merck & Co., Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3018050 Mon, 23 Nov 2009 00:00:00 +0100 3018050 http://www.medworm.com/index.php?rid=3010796&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1029%2F32%2F The U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee voted 11 to 1 that clinical data included in a supplemental new drug application (sNDA) provide substantial and convincing evidence to support the claim that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) reduces exacerbations (worsening of symptoms) in patients with chronic obstructive pulmonary disease (COPD). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3010796 Fri, 20 Nov 2009 00:00:00 +0100 3010796 http://www.medworm.com/index.php?rid=3010795&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1030%2F27%2F In 2009, 85% of online Europeans in the United Kingdom, Germany, France, Italy, and Spain turn to the Internet and other technologies for health and prescription drug information, according to the latest Cybercitizen Health® Europe v9.0 study from healthcare and pharmaceutical market research company Manhattan Research. The collaboratively-edited Wikipedia again proves to be a top online health resource for consumers in all of the countries surveyed. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3010795 Fri, 20 Nov 2009 00:00:00 +0100 3010795 http://www.medworm.com/index.php?rid=3006427&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1027%2F30%2F GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) announcedan exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX®), an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3006427 Thu, 19 Nov 2009 00:00:00 +0100 3006427 http://www.medworm.com/index.php?rid=3006426&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1028%2F32%2F AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3006426 Thu, 19 Nov 2009 00:00:00 +0100 3006426 http://www.medworm.com/index.php?rid=3002248&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1025%2F29%2F Novartis announced new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the company's influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US dose, fulfilled immune response criteria associated with protection in adults and the elderly (>=65 years of age). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3002248 Wed, 18 Nov 2009 00:00:00 +0100 3002248 http://www.medworm.com/index.php?rid=3002247&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1026%2F29%2F Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented at the American Heart Association's Scientific Sessions. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=3002247 Wed, 18 Nov 2009 00:00:00 +0100 3002247 http://www.medworm.com/index.php?rid=2998030&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1023%2F29%2F AstraZeneca announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty, (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2998030 Tue, 17 Nov 2009 00:00:00 +0100 2998030 http://www.medworm.com/index.php?rid=2998029&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1024%2F29%2F Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2998029 Tue, 17 Nov 2009 00:00:00 +0100 2998029 http://www.medworm.com/index.php?rid=2994782&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1021%2F32%2F Novartis announced the availability of Prevacid®24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn. Prevacid®24HR received US Food and Drug Administration (FDA) approval in May 2009. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2994782 Mon, 16 Nov 2009 00:00:00 +0100 2994782 http://www.medworm.com/index.php?rid=2994781&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1022%2F30%2F Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2994781 Mon, 16 Nov 2009 00:00:00 +0100 2994781 http://www.medworm.com/index.php?rid=2987360&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1019%2F30%2F Abbott (NYSE: ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2987360 Fri, 13 Nov 2009 00:00:00 +0100 2987360 http://www.medworm.com/index.php?rid=2987359&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1020%2F31%2F , with total net turnover increasing by 0.9% (3.2% in local currencies) to €820.0 million. Pantoprazole sales were resilient after losing patent protection in May in 12 European countries. On a regional basis, sales in most emerging markets exhibited strong growth. The pipeline portfolio advanced significantly. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2987359 Fri, 13 Nov 2009 00:00:00 +0100 2987359 http://www.medworm.com/index.php?rid=2983484&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1017%2F27%2F Dr. Margaret Hamburg, Commissioner of Food and Drugs, sent a letter to America's healthcare professionals thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on the safety of the 2009 H1N1 vaccines. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2983484 Thu, 12 Nov 2009 00:00:00 +0100 2983484 http://www.medworm.com/index.php?rid=2983483&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1018%2F32%2F GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted influenza A (H1N1) pandemic vaccine. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2983483 Thu, 12 Nov 2009 00:00:00 +0100 2983483 http://www.medworm.com/index.php?rid=2979590&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1016%2F30%2F Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2979590 Wed, 11 Nov 2009 00:00:00 +0100 2979590 http://www.medworm.com/index.php?rid=2975940&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1015%2F27%2F In many countries, November is diabetes awareness month, with November 14 - World Diabetes Day - the most significant date on the diabetes calendar. The need to increase diabetes awareness grows ever year with the increasing impact of the disease worldwide. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2975940 Tue, 10 Nov 2009 00:00:00 +0100 2975940 http://www.medworm.com/index.php?rid=2972858&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1013%2F27%2F At the end of September month, in Brussels, over 300 cancer organisations, patients and cancer survivors, health professionals, researchers, health authorities and health ministers gather to mark the official launch of the European Partnership for Action against Cancer. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2972858 Mon, 09 Nov 2009 00:00:00 +0100 2972858 http://www.medworm.com/index.php?rid=2972857&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1014%2F32%2F The World Health Organization (WHO) has awarded prequalification for global use of Synflorix™, GlaxoSmithKline Biologicals' pneumococcal conjugate vaccine. This is the first prequalification for a vaccine against pneumococcal disease, which is a life-threatening disease affecting many children under five in developing countries. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2972857 Mon, 09 Nov 2009 00:00:00 +0100 2972857 http://www.medworm.com/index.php?rid=2965603&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1011%2F31%2F Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the Group's limited presence in this fast-growing market segment. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2965603 Fri, 06 Nov 2009 00:00:00 +0100 2965603 http://www.medworm.com/index.php?rid=2965602&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1012%2F29%2F Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2965602 Fri, 06 Nov 2009 00:00:00 +0100 2965602 http://www.medworm.com/index.php?rid=2961614&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1010%2F30%2F Merck & Co., Inc. (NYSE: MRK) outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2961614 Thu, 05 Nov 2009 00:00:00 +0100 2961614 http://www.medworm.com/index.php?rid=2957337&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1006%2F30%2F Abbott (NYSE: ABT) has completed its acquisition of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of mitral valves. The acquisition provides Abbott with a leading presence in the growing area of non-surgical treatment for structural heart disease. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2957337 Wed, 04 Nov 2009 00:00:00 +0100 2957337 http://www.medworm.com/index.php?rid=2957336&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1007%2F29%2F Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD). (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2957336 Wed, 04 Nov 2009 00:00:00 +0100 2957336 http://www.medworm.com/index.php?rid=2957335&cid=s_38580_34_f&fid=38580&url=http%3A%2F%2Fwww.worldpharmanews.com%2Fcontent%2Fview%2F1008%2F31%2F Novartis announced a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis' long term commitment to China's further economic development, health reform and improving the health care of the Chinese people. The Novartis investment will include a significant expansion of The Novartis Institute of BioMedical Research (CNIBR) in Shanghai. (Source: World Pharma News) World Pharma News news http://www.medworm.com/rss/comments.php?id=2957335 Wed, 04 Nov 2009 00:00:00 +0100 2957335